Dr Diego Cobice has been working/contributing in the field of Mass Spectrometry (MS) for 20 years. He has obtained a Medicinal Chemistry Degree in Buenos Aires, Argentina. He was the head of the Mass Spectrometry Laboratory at Boehringer Ingelheim Pharmaceuticals R&D centre in Argentina for 5 years. After 7 years in the pharmaceutical sector, he has moved to the University of Edinburgh to pursue an MSc in applied MS to cardiovascular disease using “Mass Spectrometry Imaging” (MSI) platforms.
After completing his MSc, he continued with a PhD at University of Edinburgh under supervision of Prof Brian Walker to study the effects of 11-βHSD1 manipulation on glucocorticoids turn-over using a novel MSI platform. This research led to the first publication that achieved spatial distribution and quantification of glucocortioids in a mouse brain. These findings promoted further publications in high impact journals and research funding in the field. After completing his PhD, he worked as a Senior Research Scientist in the MSI DMPK oncology department at AstraZeneca, Cambridge,UK . Finally, he was appointed Director of the Mass Spectrometry Centre at (BMRSI) Ulster University, where he is currently in charge of centre facilities, supporting internal research and leading his own research.
His research interest is focused on the development of novel MSI platform for the identification and quantitation of novel molecular signatures in several degenerative diseases mainly focused on endocrine-related diseases to unravel new biological mechanisms that can lead to new therapeutic targets. He has published his research in high impact journals and is an invited reviewer for journals such as Journal of Chromatography and Analytical Chemistry. He is a member of British Mass Spectrometry Society (BMSS), Royal Society of Chemistry (RSC), European Society of Molecular Imaging (editor) and member of advisory board committee of the Irish Mass Spectrometry Society.
|Identification of bioactive peptides from marine sources and assessment of their potential for improving metabolic control in diabetes. Self-funded PhD Opportunity||Wednesday 1 September 2021||View Details|